DexCom, Inc. (NASDAQ:DXCM) Shares Acquired by Geneva Capital Management LLC

Geneva Capital Management LLC raised its position in DexCom, Inc. (NASDAQ:DXCM) by 3.5% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 130,668 shares of the medical device company’s stock after acquiring an additional 4,414 shares during the quarter. Geneva Capital Management LLC’s holdings in DexCom were worth $8,760,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Empowered Funds LLC grew its position in shares of DexCom by 30.7% in the 1st quarter. Empowered Funds LLC now owns 5,518 shares of the medical device company’s stock valued at $765,000 after buying an additional 1,295 shares during the last quarter. QRG Capital Management Inc. increased its position in shares of DexCom by 10.6% during the first quarter. QRG Capital Management Inc. now owns 10,896 shares of the medical device company’s stock worth $1,511,000 after purchasing an additional 1,046 shares in the last quarter. Avantax Advisory Services Inc. lifted its holdings in shares of DexCom by 35.4% in the 1st quarter. Avantax Advisory Services Inc. now owns 3,601 shares of the medical device company’s stock valued at $499,000 after purchasing an additional 942 shares during the last quarter. Bleakley Financial Group LLC boosted its position in shares of DexCom by 1.3% in the 1st quarter. Bleakley Financial Group LLC now owns 6,856 shares of the medical device company’s stock valued at $951,000 after purchasing an additional 87 shares during the period. Finally, Entropy Technologies LP purchased a new position in DexCom during the 1st quarter worth approximately $2,112,000. Institutional investors and hedge funds own 97.75% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on the stock. JPMorgan Chase & Co. raised their target price on shares of DexCom from $75.00 to $85.00 and gave the stock a “neutral” rating in a research report on Friday, October 25th. Wells Fargo & Company raised their price objective on shares of DexCom from $80.00 to $90.00 and gave the stock an “overweight” rating in a research report on Friday, October 25th. Barclays reduced their target price on shares of DexCom from $138.00 to $113.00 and set an “equal weight” rating for the company in a report on Monday, July 29th. Royal Bank of Canada dropped their price target on DexCom from $120.00 to $115.00 and set an “outperform” rating on the stock in a research report on Friday, October 25th. Finally, Canaccord Genuity Group reaffirmed a “buy” rating and set a $145.00 price objective on shares of DexCom in a research report on Tuesday, July 23rd. Seven investment analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, DexCom currently has a consensus rating of “Moderate Buy” and a consensus target price of $104.59.

DexCom Stock Up 5.7 %

DXCM opened at $74.34 on Wednesday. DexCom, Inc. has a one year low of $62.34 and a one year high of $142.00. The company has a market cap of $29.04 billion, a price-to-earnings ratio of 44.52, a PEG ratio of 2.16 and a beta of 1.17. The business’s fifty day moving average is $69.68 and its two-hundred day moving average is $92.63. The company has a debt-to-equity ratio of 1.23, a quick ratio of 2.12 and a current ratio of 2.46.

Insider Buying and Selling

In other DexCom news, COO Jacob Steven Leach sold 746 shares of the firm’s stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $69.15, for a total transaction of $51,585.90. Following the completion of the transaction, the chief operating officer now directly owns 264,915 shares in the company, valued at approximately $18,318,872.25. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. In other news, COO Jacob Steven Leach sold 746 shares of DexCom stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $69.15, for a total transaction of $51,585.90. Following the completion of the sale, the chief operating officer now directly owns 264,915 shares in the company, valued at $18,318,872.25. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Sadie Stern sold 426 shares of the stock in a transaction on Monday, September 9th. The stock was sold at an average price of $69.15, for a total value of $29,457.90. Following the transaction, the executive vice president now directly owns 75,451 shares in the company, valued at approximately $5,217,436.65. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders own 0.30% of the company’s stock.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.